Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirius Files for Australian Trials of siRNA for Thromboembolic Disorders

publication date: Nov 10, 2023

Sirius Therapeutics filed to begin a first-in-human clinical trial in Australia of SRSD107, its next-gen siRNA therapy aimed at preventing and treating thromboembolic disorders. SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA) that targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, blocking the coagulation pathway and promoting anticoagulant/anti-thrombotic effects. In preclinical in vivo tests, a single subcutaneous dose showed near 100% reduction of FXI levels for up to six months without bleeding events. Founded in 2021, Sirius has a discovery center in San Diego and a translational medicine center in Shanghai. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here